Literature DB >> 22982095

Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups.

Alejo Mancebo1, M Luisa González-Diéguez, Valle Cadahía, María Varela, Ramón Pérez, Carmen A Navascués, Nieves G Sotorríos, Maribel Martínez, Luis Rodrigo, Manuel Rodríguez.   

Abstract

BACKGROUND & AIMS: The incidence of hepatocellular carcinoma (HCC) and associated risk factors in patients with alcoholic cirrhosis are not well defined. Surveillance for HCC among patients with cirrhosis who do not have hepatitis B is cost effective only if the expected risk of HCC exceeds 1.5% per year. We performed a prospective study to determine the incidence of HCC among patients with alcoholic cirrhosis and to identify risk factors.
METHODS: We analyzed data from a surveillance program of 450 patients, aged 40 to 75 years, with alcoholic cirrhosis of Child-Pugh class A or B; patients were enrolled at the liver unit of a tertiary center from September 1992 through March 2010. Data were collected on 20 demographic, clinical, and laboratory variables at the start of the study. Patients were examined every 3 to 6 months for 5 years to identify risk factors for HCC; incidence was determined from a median follow-up time of 42 months.
RESULTS: Over the follow-up period, 62 patients developed HCC (43 in the first 5 y of follow-up evaluation), with an annual incidence of 2.6%. By using multivariate analysis, age 55 years and older (hazard ratio, 2.39; 95% confidence interval, 1.27-4.51) and platelet counts less than 125 × 10(3)/mm(3) (hazard ratio, 3.29; 95% confidence interval, 1.39-7.85) were associated independently with the development of HCC. These variables were used to define 3 risk groups. The annual incidence of HCC in the group without either of these factors was 0.3% (n = 93), the annual incidence with 1 factor was 2.6% (n = 228), and the annual incidence with both factors was 4.8% (n = 129) (P < .0001).
CONCLUSIONS: The annual incidence of HCC among patients with alcoholic cirrhosis of Child-Pugh class A or B is around 2.5%. Age and platelet count can be used to classify the patients in 3 different risk groups for HCC development within the next 5 years.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22982095     DOI: 10.1016/j.cgh.2012.09.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  49 in total

1.  Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.

Authors:  Yolanda Rodriguez Villalvazo; Jennifer S McDanel; Lauren A Beste; Antonio J Sanchez; Mary Vaughan-Sarrazin; David A Katz
Journal:  Health Serv Res       Date:  2019-11-25       Impact factor: 3.402

Review 2.  Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology).

Authors:  Aysegul Ozakyol
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 3.  Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Authors:  Pierre Nahon; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Claude Trinchet; Nathalie Ganne-Carrié
Journal:  Hepat Oncol       Date:  2015-01-12

4.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Authors:  Kristina Tzartzeva; Joseph Obi; Nicole E Rich; Neehar D Parikh; Jorge A Marrero; Adam Yopp; Akbar K Waljee; Amit G Singal
Journal:  Gastroenterology       Date:  2018-02-06       Impact factor: 22.682

Review 5.  Epidemiological and etiological variations in hepatocellular carcinoma.

Authors:  Evangelista Sagnelli; Margherita Macera; Antonio Russo; Nicola Coppola; Caterina Sagnelli
Journal:  Infection       Date:  2019-07-25       Impact factor: 3.553

Review 6.  Molecular prognostic prediction in liver cirrhosis.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Yujin Hoshida
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

7.  Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.

Authors:  Thomas Worland; Benjamin Harrison; Leighton Delmenico; Damian Dowling
Journal:  J Gastrointest Cancer       Date:  2018-12

Review 8.  Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies?

Authors:  Christine Pocha; Chencheng Xie
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-09

Review 9.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

Review 10.  Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Antonella Cammarota; Antonio D'Alessio; Tiziana Pressiani; Lorenza Rimassa; Nicola Personeni
Journal:  Drugs Aging       Date:  2021-06-21       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.